HER2-TTC was administered at a single dose of either 125 kBq/kg bw or 300 kBq/kg bw, the former selected as an inactive dose and the latter demonstrating statistically significant anti-tumor efficacy compared to control in both models. This evidence concerns the gene ERBB2 and neoplasm.